共 50 条
- [21] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124Donk, Van De N. W.Moreau, P.Garfall, A. L.Bhutani, M.Oriol, A.Nooka, A. K.Martin, T. G.Rosinol, L.Mateos, M. -V.Bahlis, N.Popat, R.Besemer, B.Lopez, Martinez J.Krishnan, A.Delforge, M.Trancucci, D.Verona, R., IStephenson, T.Chastain, K.Sidana, S.
- [22] Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study (vol 130, pg 886, 2024)CANCER, 2024, 130 (17) : 3046 - 3046Nooka, A. K.Rodriguez, C.Mateos, M., V
- [23] Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Sborov, Douglas W.Pawlyn, CharlotteIshida, TadaoHuang, Jeffrey S. Y.Benjamin, ReubenIida, ShinsukePopat, RakeshKuroda, JunyaPianko, JamesRamakrishnan, AravindSchuster, Steven RobertDabak, Vrushali S.Lesokhin, Alexander M.Conte, UmbertoSoltantabar, PoonehHong, FangxinVandendries, ErikFonseca, Rafael
- [24] Indirect treatment (tx) comparison of teclistamab (tec) in MajesTEC-1 versus physician's choice of therapy in the long-term follow-up of the CASTOR, POLLUX, EQUULEUS, and APOLLO trials in patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Mateos, Maria-VictoriaChari, AjaiUsmani, Saad ZafarGoldschmidt, HartmutWeisel, KatjaQi, KeqinLondhe, AnilNair, SandhyaLin, XiwuPei, LixiaAmmann, EricKobos, RachelSmit, JenniferParekh, Trilok V.Slavcev, MaryMoreau, Philippe
- [25] Talquetamab (tal) plus Teclistamab (tec) in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM): Updated Phase 1B Results from RedirecTT-1 With >1 Year of Follow-UpCLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S2 - S3Cohen, YaelMagen, HilaGatt, MosheSebag, MichaelKim, KihyunMin, Chang-KiOcio, EnriqueYoon, Sung-SooChu, MichaelRodriguez-Otero, PaulaAvivi, IritQuijano Carde, NataliaKrevvata, MariaPeterson, MichelleScott, EmmaHilder, BrandiVanak, JillBanerjee, ArnobOriol, AlbertMorillo, DanielMateos Manteca, Maria-Victoria
- [26] Analysis of Repeat Step-up Dosing and Cytokine Release Syndrome Events Following Prolonged Dosing Intervals of Teclistamab in the Phase 1/2 Majestec-1 StudyBLOOD, 2024, 144 : 4735 - 4735van de Donk, Niels W. C. J.Chari, AjaiKarlin, LionelKrishnan, Amrita Y.Uttervall, KatarinaChalopin, ThomasDachs, Laura RosinolOriol, AlbertMatous, Jeffrey, VBhutani, ManishaRodriguez, CesarCarde, Natalia QuijanoGuo, YueHodin, CarolineUhlar, ClarissaStephenson, TaraZuppa, AthenaDoyle, MargaretChastain, KatherineGarfall, Alfred
- [27] Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)BLOOD, 2020, 136Lonial, SagarNooka, AjayThulasi, PraneethaBadros, Ashraf Z.Jeng, Bennie H.Callander, Natalie S.Sborov, DouglasZaugg, Brian E.Popat, RakeshDegli Esposti, SimonaByrne, JulieOpalinska, JoannaBaron, JanuaryPiontek, TrishaGupta, IraDana, RezaFarooq, AsimJakubowiak, Andrzej
- [28] Updated Results From the Phase 1/2 MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple MyelomaBRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 35 - 36Popat, RakeshUsmani, Saad Z.Garfall, Alfredvan de Donk, NielsNahi, HarethSan-Miguel, Jesus F.Oriol, AlbertNooka, AjayMartin, ThomasRosinol, LauraChari, AjaiKarlin, LionelBenboubker, LotfiMateos, Maria-VictoriaBahlis, NizarMoreau, PhilippeBesemer, BrittaMartinez-Lopez, JoaquinSidana, SurbhiPei, LixiaTrancucci, DanielleVerona, RalucaGirgis, SuzetteOlyslager, YunsiJaffe, MindyUhlar, ClarissaStephenson, TaraVan Rampelbergh, RianBanerjee, ArnobGoldberg, Jenna D.Kobos, RachelKrishnan, Amrita
- [29] KarMMa study: Characterization of Cytokine Release Syndrome (CRS) in patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with Idecabtagene Vicleucel (ide-cel, bb2121)ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 208 - 209Einsele, H.Kansagra, A.Lin, Y.Berdeja, J.Shah, N.Oriol, A.Yakoub-Agha, IRambaldi, A.Truppel-Hartmann, A.Rowe, E.Wang, J.Agarwal, A.Campbell, T. B.Lonial, S.
- [30] Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple MyelomaBLOOD, 2021, 138Moreau, PhilippeUsmani, Saad Z.Garfall, Alfred L.van de Donk, Niels W. C. J.Nahi, HarethSan-Miguel, JesusOriol, AlbertNooka, Ajay K.Martin, ThomasRosino, LauraChari, AjaiKarlin, LionelBenboubker, LotfiMateos, Maria-VictoriaBahlis, Nizar J.Popat, RakeshBesemer, BrittaMartínez-López, JoaquínSidana, SurbhiPei, LixiaTrancucci, DanielleVerona, Raluca I.Girgis, SuzetteOlyslager, YunsiJaffe, MindyUhlar, Clarissa M.Stephenson, TaraVan Rampelbergh, RianBanerjee, ArnobGoldberg, Jenna D.Kobos, RachelKrishnan, Amrita Y.